-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Rheumatic arthritis (rheumatic arthritis, RA) is a common type of acute or chronic connective tissue inflammation.
it usually causes joint fever, swelling and pain.
most common are wrists and hands that involve the same joints on both sides of the body.
the disease may also affect other parts of the body.
this can lead to low red blood cells, inflammation of the lungs, and inflammation of the heart.
may also have fever and lack of vitality.
usually symptoms are gradually more than a few weeks to months.
Gilead Sciences announced Friday that the European Commission has approved Jyseleca (filgotinib) to treat adult patients with moderate to severe active rheumatoid arthritis (RA) who do not respond adequately to one or more treatments.
said earlier in the day that Japanese regulators had approved Jyseleca's treatment of RA patients who did not respond well to conventional therapies.
Jyseleca (filgotinib) is an oral JAK1 inhibitor that Gilead is developing once a day.
both approvals are based on the latest results from phase III FINCH and Phase II DARWIN studies, which showed improved clinical symptoms and signs in patients receiving Jyseleca (filgotinib) and reduced disease activity.
in Japan, Gilead will be in charge of Jyseleca's supply, while Eisai will be responsible for product distribution.
.